AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

• Status: Completed
• Trial end date: 2012-04-01

Summary

The primary objectives of this study are the following:

Phase 1b: To identify a safe dose level of AMG 102, up to 15 mg/kg Q3W, to combine with mitoxantrone and prednisone (MP) Phase 2: To estimate with adequate precision the effect of the addition of AMG 102 to MP, compared with placebo plus MP, as assessed by the hazard ratio (HR) for overall survival (OS) of previously treated subjects with castrate-resistant prostate cancer (CRPC)

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Amgen
• Treatments: Antibodies, Monoclonal; Mitoxantrone; Prednisone; Rilotumumab